From The Editors June 2022

TON - June 2022 Vol 15, No 3
Catherine S Bishop, DNP, NP, AOCNP
Hematology/Oncology Nurse Practitioner

In this issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles designed to inform and empower nurses, navigators, and advanced practice providers who work to improve the clinical outcomes and quality of life of patients in all stages of the cancer care journey.

Since June is National Cancer Survivor Month, we begin this issue with an interview with Sandy Camarota, MSN, CRNP, AOCNP, Oncology Nurse Practitioner and Survivorship Program Coordinator at Abramson Cancer Center at Penn Medicine Chester County Hospital, West Chester, PA, who discusses the wide array of services available at her cancer center to ensure that patients have the knowledge and support they need to successfully transition from active treatment to survivorship care (see here).

This issue of TON also includes coverage from several national and international oncology meetings, where experts presented key data on drugs and combination regimens being used to extend survival for patients with cancer. In a session during the 2022 American Association for Cancer Research annual meeting, Grace K. Dy, MD, Chief of Thoracic Oncology and Professor of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discussed updated results from the phase 2 CodeBreaK 100 trial, which highlighted the impressive efficacy of sotorasib for the treatment of patients with metastatic non–small-cell lung cancer with KRAS p.G12C mutation (see here).

“This is the longest follow-up for a KRASG12C inhibitor, including 2-year survival, updated safety, and genomic profiles in patients with durable clinical benefit. Thirty-two percent of patients treated with sotorasib had a survival of 2 years or more,” she noted during her presentation.

During the National Comprehensive Cancer Network 2022 Annual Conference, Reid Ness, MD, MPH, Associate Professor of Medicine, Vanderbilt University Medical Center, Nashville, TN, discussed important updates to screening guidelines for colorectal cancer, including the decision to lower the recommended age for initial screen from 50 years to 45 years for average-risk individuals (see here).

We also examine the need for more inclusive approaches to designing, recruiting for, and implementing clinical trials, which can help address the problem of underrepresentation of many minority and marginalized communities (see here).

As always, we hope that you will enjoy this issue of TON, and we invite you to visit to share your feedback with us. You can also send an e-mail with any questions or comments you may have to

Related Items

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: